17 Analysts Have This To Say About Crinetics Pharmaceuticals
Portfolio Pulse from Benzinga Insights
17 analysts have provided ratings for Crinetics Pharmaceuticals (NASDAQ:CRNX), with a mix of bullish and somewhat bullish perspectives. The average 12-month price target is $64.06, reflecting an 18.45% increase from the previous target. Despite positive analyst sentiment, the company faces financial challenges, including a significant revenue decline and negative profitability metrics.
June 04, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Crinetics Pharmaceuticals (NASDAQ:CRNX) has received a mix of bullish and somewhat bullish ratings from 17 analysts, with an average 12-month price target of $64.06. However, the company faces significant financial challenges, including a 76.11% decline in revenue growth and negative profitability metrics.
The positive analyst ratings and increased price targets suggest a short-term upward movement in CRNX's stock price. However, the company's financial challenges, including a significant revenue decline and negative profitability metrics, may limit the extent of this positive impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100